{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:09:31Z","timestamp":1779336571108,"version":"3.51.4"},"reference-count":41,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/jqqx7009","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:11:22Z","timestamp":1774858282000},"page":"1846-1862","source":"Crossref","is-referenced-by-count":0,"title":["A novel prognostic signature based on epithelial-mesenchymal transition-associated genes for the prognosis and immune status in breast cancer"],"prefix":"10.62347","volume":"18","author":[{"given":"Zizheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu","year":"2023","unstructured":"Xu Y, Gong M, Wang Y, Yang Y, Liu S and Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data 2023; 10: 334.","journal-title":"Sci Data"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the ajcc cancer staging manual: breast cancer","volume":"25","author":"AE","year":"2018","unstructured":"Giuliano AE, Edge SB and Hortobagyi GN. Eighth edition of the ajcc cancer staging manual: breast cancer. Ann Surg Oncol 2018; 25: 1783-1785.","journal-title":"Ann Surg Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X and Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol 2020; 60: 14-27.","journal-title":"Semin Cancer Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","article-title":"Mutational drivers of cancer cell migration and invasion","volume":"124","author":"Novikov","year":"2021","unstructured":"Novikov NM, Zolotaryova SY, Gautreau AM and Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer 2021; 124: 102-114.","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","unstructured":"Viallard C and Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 2017; 20: 409-426.","journal-title":"Angiogenesis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","unstructured":"Dongre A and Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019; 20: 69-84.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","article-title":"Epithelial mesenchymal transition in tumor metastasis","volume":"13","author":"Mittal","year":"2018","unstructured":"Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol 2018; 13: 395-412.","journal-title":"Annu Rev Pathol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/med.21948","article-title":"Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds","volume":"43","author":"Ang","year":"2023","unstructured":"Ang HL, Mohan CD, Shanmugam MK, Leong HC, Makvandi P, Rangappa KS, Bishayee A, Kumar AP and Sethi G. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev 2023; 43: 1141-1200.","journal-title":"Med Res Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/jcp.25797","article-title":"Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis","volume":"232","author":"Chen","year":"2017","unstructured":"Chen T, You Y, Jiang H and Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol 2017; 232: 3261-3272.","journal-title":"J Cell Physiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"Emt transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","unstructured":"Pastushenko I and Blanpain C. Emt transition states during tumor progression and metastasis. Trends Cell Biol 2019; 29: 212-226.","journal-title":"Trends Cell Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","article-title":"Epithelial-mesenchymal plasticity in cancer progression and metastasis","volume":"49","author":"Lu","year":"2019","unstructured":"Lu W and Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell 2019; 49: 361-374.","journal-title":"Dev Cell"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","article-title":"RHOJ controls EMT-associated resistance to chemotherapy","volume":"616","author":"Debaugnies","year":"2023","unstructured":"Debaugnies M, Rodríguez-Acebes S, Blondeau J, Parent MA, Zocco M, Song Y, de Maertelaer V, Moers V, Latil M, Dubois C, Coulonval K, Impens F, Van Haver D, Dufour S, Uemura A, Sotiropoulou PA, Méndez J and Blanpain C. RHOJ controls EMT-associated resistance to chemotherapy. Nature 2023; 616: 168-175.","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","article-title":"Linking emt programmes to normal and neoplastic epithelial stem cells","volume":"21","author":"Lambert","year":"2021","unstructured":"Lambert AW and Weinberg RA. Linking emt programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer 2021; 21: 325-338.","journal-title":"Nat Rev Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1101\/gr.135350.111","article-title":"GENCODE: the reference human genome annotation for the encode project","volume":"22","author":"Harrow","year":"2012","unstructured":"Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C, Harte R, Lin M, Howald C, Tanzer A, Derrien T, Chrast J, Walters N, Balasubramanian S, Pei B, Tress M, Rodriguez JM, Ezkurdia I, van Baren J, Brent M, Haussler D, Kellis M, Valencia A, Reymond A, Gerstein M, Guigó R and Hubbard TJ. GENCODE: the reference human genome annotation for the encode project. Genome Res 2012; 22: 1760-1774.","journal-title":"Genome Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/bioinformatics\/btp692","article-title":"RNA-seq gene expression estimation with read mapping uncertainty","volume":"26","author":"Li","year":"2010","unstructured":"Li B, Ruotti V, Stewart RM, Thomson JA and Dewey CN. RNA-seq gene expression estimation with read mapping uncertainty. Bioinformatics 2010; 26: 493-500.","journal-title":"Bioinformatics"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kidd AC, Mcgettrick M, Tsim S, Halligan DL, Bylesjo M and Blyth KG. Survival prediction in mesothelioma using a scalable lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respir Res 2018; 5: e240.","DOI":"10.1136\/bmjresp-2017-000240"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12: 453-457.","journal-title":"Nat Methods"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB and Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612.","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-15550.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1528690","DOI":"10.3389\/fimmu.2025.1528690","article-title":"The association of systemic immune-inflammation index with incident breast cancer and all-cause mortality: evidence from a large population-based study","volume":"16","author":"Li","year":"2025","unstructured":"Li Y, Yu M, Yang M and Yang J. The association of systemic immune-inflammation index with incident breast cancer and all-cause mortality: evidence from a large population-based study. Front Immunol 2025; 16: 1528690.","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","article-title":"Breast cancer metastasis: mechanisms and therapeutic implications","volume":"23","author":"Park","year":"2022","unstructured":"Park M, Kim D, Ko S, Kim A, Mo K and Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci 2022; 23: 6806.","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1002\/jcp.26847","article-title":"Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity","volume":"233","author":"Hong","year":"2018","unstructured":"Hong D, Fritz AJ, Zaidi SK, van Wijnen AJ, Nickerson JA, Imbalzano AN, Lian JB, Stein JL and Stein GS. Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. J Cell Physiol 2018; 233: 9136-9144.","journal-title":"J Cell Physiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ejso.2018.12.019","article-title":"Prognostic and clinical significance of syndecan-1 expression in breast cancer: a systematic review and meta-analysis","volume":"45","author":"Qiao","year":"2019","unstructured":"Qiao W, Liu H, Guo W, Li P and Deng M. Prognostic and clinical significance of syndecan-1 expression in breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2019; 45: 1132-1137.","journal-title":"Eur J Surg Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.biochi.2022.01.014","article-title":"Syndecan-1 and -4 influence wnt signaling and cell migration in human breast cancers","volume":"198","author":"Pham","year":"2022","unstructured":"Pham SH, Pratt K, Okolicsanyi RK, Oikari LE, Yu C, Peall IW, Arif KT, Chalmers TA, Gyimesi M, Griffiths LR and Haupt LM. Syndecan-1 and -4 influence wnt signaling and cell migration in human breast cancers. Biochimie 2022; 198: 60-75.","journal-title":"Biochimie"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11010-020-04015-y","article-title":"The role of high mobility group protein b3 (HMGB3) in tumor proliferation and drug resistance","volume":"476","author":"Wen","year":"2021","unstructured":"Wen B, Wei YT and Zhao K. The role of high mobility group protein b3 (HMGB3) in tumor proliferation and drug resistance. Mol Cell Biochem 2021; 476: 1729-1739.","journal-title":"Mol Cell Biochem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1048921","DOI":"10.3389\/fonc.2022.1048921","article-title":"Overexpression of HMGB3 and its prognostic value in breast cancer","volume":"12","author":"Zhou","year":"2022","unstructured":"Zhou X, Zhang Q, Liang G, Liang X and Luo B. Overexpression of HMGB3 and its prognostic value in breast cancer. Front Oncol 2022; 12: 1048921.","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.3390\/ijms23169365","article-title":"The function of n-myc downstream-regulated gene 2 (NDRG2) as a negative regulator in tumor cell metastasis","volume":"23","author":"KW","year":"2022","unstructured":"Lee KW, Lim S and Kim KD. The function of n-myc downstream-regulated gene 2 (NDRG2) as a negative regulator in tumor cell metastasis. Int J Mol Sci 2022; 23: 9365.","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/jcp.2009.067298","article-title":"Loss of alx4 expression in epithelial cells and adjacent stromal cells in breast cancer","volume":"62","author":"Chang","year":"2009","unstructured":"Chang H, Mohabir N, Done S and Hamel PA. Loss of alx4 expression in epithelial cells and adjacent stromal cells in breast cancer. J Clin Pathol 2009; 62: 908-914.","journal-title":"J Clin Pathol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13046-017-0643-9","article-title":"Alx4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering wnt\/β-catenin pathway","volume":"36","author":"Yang","year":"2017","unstructured":"Yang J, Han F, Liu W, Chen H, Hao X, Jiang X, Yin L, Huang Y, Cao J, Zhang H and Liu J. Alx4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering wnt\/β-catenin pathway. J Exp Clin Cancer Res 2017; 36: 170.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"17500","DOI":"10.1074\/jbc.M400802200","article-title":"Structure-function analysis of the reactive site in the first kunitz-type domain of human tissue factor pathway inhibitor-2","volume":"279","author":"Chand","year":"2004","unstructured":"Chand HS, Schmidt AE, Bajaj SP and Kisiel W. Structure-function analysis of the reactive site in the first kunitz-type domain of human tissue factor pathway inhibitor-2. J Biol Chem 2004; 279: 17500-17507.","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10020-020-00158-2","article-title":"TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway","volume":"26","author":"Zhao","year":"2020","unstructured":"Zhao D, Qiao J, He H, Song J, Zhao S and Yu J. TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway. Mol Med 2020; 26: 27.","journal-title":"Mol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00428-018-2324-2","article-title":"P63 isoforms in triple-negative breast cancer: δnp63 associates with the basal phenotype whereas tap63 associates with androgen receptor, lack of brca mutation, pten and improved survival","volume":"472","author":"Coates","year":"2018","unstructured":"Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M and Vojtesek B. P63 isoforms in triple-negative breast cancer: δnp63 associates with the basal phenotype whereas tap63 associates with androgen receptor, lack of brca mutation, pten and improved survival. Virchows Arch 2018; 472: 351-359.","journal-title":"Virchows Arch"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/biom12091183","article-title":"Reduced expression of KRT17 predicts poor prognosis in her2(high) breast cancer","volume":"12","author":"Tang","year":"2022","unstructured":"Tang S, Liu W, Yong L, Liu D, Lin X, Huang Y, Wang H and Cai F. Reduced expression of KRT17 predicts poor prognosis in her2(high) breast cancer. Biomolecules 2022; 12: 1183.","journal-title":"Biomolecules"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1131525","DOI":"10.3389\/fendo.2023.1131525","article-title":"A large-scale screening and functional sorting of tumour microenvironment prognostic genes for breast cancer patients","volume":"14","author":"Xiao","year":"2023","unstructured":"Xiao B, Li M, Cui M, Yin C and Zhang B. A large-scale screening and functional sorting of tumour microenvironment prognostic genes for breast cancer patients. Front Endocrinol (Lausanne) 2023; 14: 1131525.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"19352","DOI":"10.1002\/jcp.28657","article-title":"NK cells: an attractive candidate for cancer therapy","volume":"234","author":"Valipour","year":"2019","unstructured":"Valipour B, Velaei K, Abedelahi A, Karimipour M, Darabi M and Charoudeh HN. NK cells: an attractive candidate for cancer therapy. J Cell Physiol 2019; 234: 19352-19365.","journal-title":"J Cell Physiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"SY","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ and Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer 2020; 19: 120.","journal-title":"Mol Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1007\/s11033-022-07865-5","article-title":"The role of the natural killer (NK) cell modulation in breast cancer incidence and progress","volume":"49","author":"Razeghian","year":"2022","unstructured":"Razeghian E, Kameh MC, Shafiee S, Khalafi F, Jafari F, Asghari M, Kazemi K, Ilkhani S, Shariatzadeh S and Haj-Mirzaian A. The role of the natural killer (NK) cell modulation in breast cancer incidence and progress. Mol Biol Rep 2022; 49: 10935-10948.","journal-title":"Mol Biol Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3892\/or.2020.7840","article-title":"Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase-type plasminogen activator","volume":"45","author":"Jin","year":"2021","unstructured":"Jin H, Choi H, Kim ES, Lee HH, Cho H and Moon A. Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase-type plasminogen activator. Oncol Rep 2021; 45: 299-308.","journal-title":"Oncol Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1083462","DOI":"10.3389\/fimmu.2022.1083462","article-title":"Focusing on NK cells and adcc: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer","volume":"13","author":"Li","year":"2022","unstructured":"Li F and Liu S. Focusing on NK cells and adcc: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. Front Immunol 2022; 13: 1083462.","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH and de Reyniès A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016; 17: 218.","journal-title":"Genome Biol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:45:28Z","timestamp":1779335128000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/18\/3\/ajtr0168992.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.62347\/jqqx7009","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}